The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores
Open accessAbstract
Background & Aims Hepatocellular carcinoma (HCC) risk stratification in individuals with dysmetabolism is a major unmet need. Genetic predisposition contributes to non-alcoholic fatty liver disease (NAFLD). We aimed to exploit robust polygenic risk scores (PRS) that can be evaluated in the clinic to gain insight into the causal relationship between NAFLD and HCC, and to improve HCC risk stratification. Methods We examined at-risk individuals (NAFLD cohort, n = 2,566; 226 with HCC; and a replication cohort of 427 German patients with NAFLD) and the general population (UK Biobank [UKBB] cohort, n = 364,048; 202 with HCC). Variants in PNPLA3-TM6SF2-GCKR-MBOAT7 were combined in a hepatic fat PRS (PRS-HFC), and then adjusted for HSD17B13 (PRS-5). Results In the NAFLD cohort, the adjusted impact of genetic risk variants on HCC was proportional to the predisposition to fatty liver ( p = 0.002) with some heterogeneity in the effect. PRS predicted HCC more robustly than single variants ( p < 10 -13 ). The association between PRS and HCC was mainly mediated through severe fibrosis, but was independent of fibrosis in clinically relevant subgroups, and was also observed in those without severe fibrosis ( p < 0.05). In the UKBB cohort, PRS predicted HCC independently of classical risk factors and cirrhosis ( p < 10 -7 ). In the NAFLD cohort, we identified high PRS cut-offs (≥0.532/0.495 for PRS-HFC/PRS-5) that in the UKBB cohort detected HCC with ~90% specificity but limited sensitivity; PRS predicted HCC both in individuals with ( p < 10 -5 ) and without cirrhosis ( p < 0.05). Conclusions Our results are consistent with a causal relationship between hepatic fat and HCC. PRS improved the accuracy of HCC detection and may help stratify HCC risk in individuals with dysmetabolism, including those without severe liver fibrosis. Further studies are needed to validate our findings. Lay summary By analyzing variations in genes that contribute to fatty liver disease, we developed two risk scores to help predict liver cancer in individuals with obesity-related metabolic complications. These risk scores can be easily tested in the clinic. We showed that the risk scores helped to identify the risk of liver cancer both in high-risk individuals and in the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Comprehensive polygenic risk scores are superior to PNPLA3 and TM6SF2 alone for risk prediction of progressive MASLD, especially in individuals with metabolic triggers, and the bene fi ts of their use over clinical risk factors alone becomes more evident for long-term prediction. 196,206,207”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [206]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Another model incorporated genetic variants in a risk score that predicted HCC independently of classical risk factors, but the AUROC when used alone was only 0.65. 206”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [206]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
The UK Biobank resource with deep phenotyping and genomic data
Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O’Connell, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0579-z · Cited by 8,876
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians
Davies, N. M., Holmes, M. V., & Davey Smith, G. (2018) · BMJ · doi:10.1136/bmj.k601 · Cited by 4,404
Flagged first, then by citations
1 of the 37 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 385
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers
Terracciani, F., Falcomatà, A., Gallo, P., Picardi, A., & Gentilucci, U. V. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-022-00934-0 · Cited by 9
Genetic Markers Predisposing to Nonalcoholic Steatohepatitis
Sohal, A., Chaudhry, H., & Kowdley, K. V. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.006 · Cited by 9
Genetics: A new clinical tool for the hepatologist
Valenti, L. V. C., & Ronzoni, L. (2022) · Liver International · doi:10.1111/liv.15205 · Cited by 8
TINIAKOS, D. G., Anstee, Q. M., Brunt, E. M., & Burt, A. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00005-3 · Cited by 7
Hepatocellular Carcinoma Surveillance
Koo, E., & Singal, A. G. (2023) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2023.06.005 · Cited by 7
Zou, Y., Zhu, J., Song, C., Li, T., Wang, K., Shi, J., Ye, H., & Wang, P. (2024) · Cancer Medicine · doi:10.1002/cam4.7230 · Cited by 7
MetALD: Genetic Factors and Clinical Outcomes
Israelsen, M. E., Trépo, E., Krag, A. A., & Stender, S. (2025) · Seminars in Liver Disease · doi:10.1055/a-2630-0952 · Cited by 7
Polymorphism’s MBOAT7 as Risk and MTARC1 as Protection for Liver Fibrosis in MASLD
Rocha, S., de Oliveira, C. P. M. S., Stefano, J. T., Yokogawa, R. P., Gomes‐Gouvêa, M. S., Zitelli, P. M., da Silva-Etto, J. M. K., Martins, E. D., Pessôa, M. G., Alcantara, F. F., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136406 · Cited by 9
Link between type 2 diabetes mellitus and hepatocellular carcinoma
Giri, S., Mukhuty, A., Mondal, S. A., Sahoo, J., Roy, A., Kamalanathan, S., & Naik, D. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.107675 · Cited by 7
Torre, P., Motta, B. M., Sarcina, T., Festa, M., Masarone, M., & Persico, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178426 · Cited by 7
Lin, Y., Lin, Y., Chen, Y., Chen, Y. A., Chen, I.-C., Tsai, H., Chen, C. H., Lee, S., Yang, H., & Lee, T. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70566 · Cited by 7
Lipid droplets as the genetic nexus of fatty liver
Mann, J. P., Romeo, S., & Valenti, L. V. C. (2022) · Liver International · doi:10.1111/liv.15460 · Cited by 7
Mújica, E., & den Hoed, M. (2023) · Liver International · doi:10.1111/liv.15752 · Cited by 7
Wang, P., Li, Y., Lu, L., Zhong, R., & Shen, N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.639438 · Cited by 7
HCC in metabolic syndrome: current concepts and future directions
Zampaglione, L., Ferrari, J., Pedica, F., & Goossens, N. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2021.22 · Cited by 7
Zuo, D., An, H., Li, J., Xiao, J., & Ren, L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111143 · Cited by 7
Molecular mechanisms of liver carcinogenesis related to metabolic syndrome
Campani, C., & Nault, J. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2021.126 · Cited by 4
Nischalke, H. D., Schmalz, F., Buch, S., Fischer, J., Möller, C., Matz‐Soja, M., Krämer, B., Langhans, B., Klüners, A., Soyka, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315353 · Cited by 7
Schmalz, F., Fischer, J., Innes, H. A., Buch, S., Möller, C., Matz‐Soja, M., Schönfels, W. V., Krämer, B., Langhans, B., Klüners, A., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100684 · Cited by 7
PNPLA3 I148M and Hepatocellular Carcinoma
Tavaglione, F., Pennisi, G., & Pelusi, S. (2025) · Liver International · doi:10.1111/liv.70051 · Cited by 6
Jiang, J., Liu, Y., Yang, H., Ma, Z., Liu, W., Zhao, M., Peng, X., Qin, X., & Yang, X. (2025) · Food Research International · doi:10.1016/j.foodres.2025.116497 · Cited by 7
Complexity of metabolic dysfunction–associated steatotic liver disease: State of the art review
Yeh, H., Lin, S. J., Shen, H., Li, T., Tsai, H., Yang, Y., Lin, H.-C., & Hou, M. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001254 · Cited by 6
Dj, H., Zhang, Z., Dorajoo, R., Khor, C. C., Pham, Y. T., Wang, R., Behari, J., Yuan, J., Koh, W., & Luu, H. N. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70532 · Cited by 6
Liu, Z., Huang, H., Xie, J., & Xu, C. (2023) · Liver International · doi:10.1111/liv.15564 · Cited by 6
Karsdal, M. A., Hallsworth, K., Scragg, J. H., Leeming, D. J., Villesen, I. F., Avery, L., Haigh, L., Govaere, O., Wichmann, S., Taylor, G., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000254 · Cited by 6
NAFLD and HCC: Time to Bridge the Gap
Cholankeril, G. T., & Kanwal, F. (2021) · Hepatology · doi:10.1002/hep.32025 · Cited by 6
Lee, H. A. (2024) · Ewha Medical Journal · doi:10.12771/emj.2024.e65 · Cited by 5
Hydes, T., Cuthbertson, D. J., Palmer, D. H., Elshaarawy, O., Johnson, P. J., Fernando, R., & Cross, T. (2023) · Hepatoma Research · doi:10.20517/2394-5079.2022.97 · Cited by 5
Gentilucci, U. V., Valenti, L. V. C., & Romeo, S. (2023) · Liver International · doi:10.1111/liv.15697 · Cited by 4
Lani, L., Zaccherini, G., Giannini, E. G., & Trevisani, F. (2025) · Hepatoma Research · doi:10.20517/2394-5079.2024.136 · Cited by 5
Burlone, M. E., Bellan, M., Barbaglia, M. N., Mocchetti, G., Mallela, V. R., Minisini, R., Rigamonti, C., & Pirisi, M. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-021-01578-1 · Cited by 5
Cholankeril, G. T., & El‐Serag, H. B. (2022) · Seminars in Liver Disease · doi:10.1055/a-1957-8540 · Cited by 5
Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma
Akl, M. G., & Widenmaier, S. B. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1089124 · Cited by 6
Lv, Y., Ding, D., Luo, M., Tan, X. W., Yang, X., & Chen, L. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.011 · Cited by 5
Åberg, F. O., Saarinen, K., Jula, A., Lundqvist, A., Vihervaara, T., Erlund, I., & Färkkilä, M. A. (2023) · Liver International · doi:10.1111/liv.15681 · Cited by 5
The Growing Landscape of NAFLD-Associated Hepatocellular Carcinoma and Its Impact in Surveillance
Machado, M. V. (2023) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000531397 · Cited by 6
Ronzoni, L., Mureddu, M., Malvestiti, F., Moretti, V., Bianco, C., Periti, G., Baldassarri, M., Ariani, F., Carrer, A., Pelusi, S., et al. (2023) · Genes · doi:10.3390/genes14081633 · Cited by 5
NASH/NAFLD-Related Hepatocellular Carcinoma: An Added Burden
Georgescu, D., Lighezan, D., Rosca, C. I., Nistor, D., Ancusa, O., Suceava, I., Iancu, M. A., & Kundnani, N. R. (2023) · Life · doi:10.3390/life14010025 · Cited by 6
Are we ready for genetic testing in metabolic dysfunction‐associated steatotic liver disease?
Tulone, A., Pennisi, G., Ciccioli, C., Infantino, G., Mantia, C. L., Cannella, R., Mercurio, F., & Petta, S. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12556 · Cited by 5
Yu, C., Tang, Y., Liu, M., Xu, X., Ge, X., Ma, H., Jin, G., Shen, H., Song, C., & Hu, Z. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02144-5 · Cited by 6
Piciotti, R., Longo, M., Agresta, A., Paolini, E., Cespiati, A., Meroni, M., & Dongiovanni, P. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2022.46 · Cited by 6
Rowe, I. A. C., & D’Amico, G. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.038 · Cited by 5
Kim, D. Y., Zhang, H., Lee, J. S., Lee, H. W., Kim, B. K., Kim, B. K., Kim, S. U., Kim, D. Y., Ahn, S. H., Gee, H. Y., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101713 · Cited by 8
Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice
Yin, X., Bickerton, C., MacDonald, B. T., Arduini, A., Shi, Y., Haas, M., Deik, A., Chaffin, M. D., Kovacs-Bogdan, E., Ávila-Pacheco, J., et al. (2026) · Liver International · doi:10.1111/liv.70507 · Cited by 4
Liu, W., Xu, X., Chang, Q. H., Yang, H., Ma, Z., Zhang, T., Zhao, Y., Zhao, L., & Xia, Y. (2026) · Nutrition Journal · doi:10.1186/s12937-026-01289-8 · Cited by 4
Genetics of MASLD: a diabetes perspective
Bilson, J., & Yaghootkar, H. (2026) · Diabetologia · doi:10.1007/s00125-026-06759-6 · Cited by 8
Jacobson, I. M., Wong, V. W., Castéra, L., Anstee, Q. M., Noureddin, M., Cusi, K. J., Harrison, S. A., Bugianesi, E., & Younossi, Z. M. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001780 · Cited by 4
Llamoza-Torres, C. J., Fuentes-Pardo, M., & Ramos‐Molina, B. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.64 · Cited by 6
Genetic Risk Factors for Steatotic Liver Disease After Liver Transplantation
Liukkonen, V., Semenova, M., Hyvärinen, K., Lauronen, J., Partanen, J., Arola, J. T., Nordin, A. J., Färkkilä, M. A., & Åberg, F. O. (2025) · Liver International · doi:10.1111/liv.70067 · Cited by 4
The utility of hierarchical genetic testing in paediatric liver disease
Wang, F., Li, Y., Zhao, S., Dong, Y., Chen, Z., Xu, Z., Wang, L., Zhu, S., Zhang, T. J., Jianguo, Y., et al. (2022) · Liver International · doi:10.1111/liv.15235 · Cited by 4
Desjonqueres, E., & Gigante, E. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2021.136 · Cited by 4
Clusmann, J., Koop, P., Zhang, D. Y., van Haag, F., Nahhas, O. S. M. E., Seibel, T., Žigutytė, L., Kaewdech, A., Caldéraro, J., Tacke, F., et al. (2024) · medRxiv · doi:10.1101/2024.11.03.24316662 · Cited by 4
Bringing genetic testing into the clinical management of people with MASLD: Are we there yet?
Valenti, L. V. C., & Hagström, H. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.05.016 · Cited by 5
Angelini, G., Panunzi, S., Pompili, M., Riccardi, L., Garcovich, M., Verrastro, O., Russo, S. L. M. L., Mare, T. A., Luxton, J., le Roux, C. W., et al. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae208 · Cited by 3
Jang, T., Wang, C., Liang, P., Wei, Y., Yeh, M., Lin, Y., Huang, C., Tsai, P., Ko, Y., Tsai, Y., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70021 · Cited by 3
Foundations of Artificial Intelligence in Hepatology: What a Clinician Needs to Know?
Peng, N., Song, S. J., Hui, V. W., Lai, J. C., Wong, G. L., Wong, V. W., & Yip, T. C. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103183 · Cited by 4
Xue, H., Wang, L., Wu, Y., Liao, Y., Wang, S., Chen, A., Chan, S. O., Ling, W., Chen, X., & Yu, C. (2025) · Hepatology · doi:10.1097/hep.0000000000001628 · Cited by 4
Pelusi, S., Macchi, C., Malvestiti, F., Margarita, S., Matteis, I. D., Periti, G., Rondena, J., Mira, S., Iemma, F., Tranchina, M., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03004-z · Cited by 4
Gu, M., Yu, B., Liu, H., & Kong, H. (2026) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2026.127625 · Cited by 3
Monogenic and Polygenic Risk in Common Liver Diseases: Implications for Clinical Care
Ajmera, V. H., Huang, D. Q., Chen, V. L., & Reddy, K. R. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.03.020 · Cited by 3
Troisi, J., Torre, P., Schiavo, L., Motta, B. M., Lombardi, M., Festa, M., Sarcina, T., Masarone, M., & Persico, M. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106672 · Cited by 3
Bromfield, B. B., CHIMENE-WEISS, J. I., Gheewalla, G., Feldman, T., Mitten, E. K., Portincasa, P., & Baffy, G. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103921 · Cited by 3
Ronzoni, L., Pelusi, S., Moretti, V., Malvestiti, F., Torghabehei, H. E., Jamialahmadi, O., Rondena, J., Bianco, C., Periti, G., Filippo, M. R. D., et al. (2025) · Liver International · doi:10.1111/liv.70010 · Cited by 3
Samarasinghe, S. M., Hewage, A. S., Siriwardana, R. C., Tennekoon, K. H., Niriella, M. A., Silva, S. D., & Abeysuriya, V. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03738-w · Cited by 3
Cruz, A. A., Hernández, J. C. N., Garza, L. E. C., Miranda‐Duarte, A., Mata-Tijerina, V., Hernández-García, M. E., Peñuelas-Urquides, K., González-Escalante, L. A., de León, M. B., & Silva-Ramírez, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157409 · Cited by 3
Risk Stratification for Hepatocellular Carcinoma in Patients with Non-alcoholic Fatty Liver Disease
Truong, E., Han, C., Muthiah, M. D., & Noureddin, M. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00595-7 · Cited by 3
Wang, H., Li, Y., Pu, X., Liang, X. S., Tang, R., & Ma, X. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02045-z · Cited by 3
Lai, M., Qin, Y.-L., Jin, Q.-Y., Chen, W., & Hu, J. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i12.2225 · Cited by 3
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
Teng, M. L. P., Tan, D. J. H., Ng, C. H., & Huang, D. Q. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0069 · Cited by 3
Sex-separated NAFLD/NASH Scores May Improve Predictive Performance
Jeong, S., Kim, H. J., & Han, H. W. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.04.041 · Cited by 3
Wiegand, J., Petroff, D., & Karlas, T. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12520 · Cited by 3
Lee, Y., Tseng, H., & Yang, J. D. (2024) · Hepatology · doi:10.1097/hep.0000000000000898 · Cited by 3
Song, Y., Chen, H., Li, J., Zhong, F., Liu, Y., Liu, H., & Wan, S. (2024) · Journal of Viral Hepatitis · doi:10.1111/jvh.14008 · Cited by 2
Chotiprasidhi, P., Nartey, Y. A., Sato‐Espinoza, K., Vierkant, R. A., Ma, J., Awuku, Y. A., Agyei-Nkansah, A. A., Afihene, M., Duah, A., Bampoh, S. A., et al. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100639 · Cited by 2
The impact of genetic and environmental risk factors on adverse liver outcomes
Zhang, X., Zhao, L., Campbell, P. T., Chen, Y., Fang, A., Liu, Z., Li, X., Yang, W., Fan, J., Petrick, J. L., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70259 · Cited by 2
Du, M., Wu, T., Yuan, H., Zhang, T., Liu, Z., & Chen, X. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00638 · Cited by 2
Liang, Z., Jin, H., Gao, W., Zhang, H., Hu, X., Li, R., Li, X., Cheng, Y., Guo, L., & Liu, Y. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00677 · Cited by 2
Lee, T., Song, S. J., Ho, H. J., Wong, G. L., Hsu, Y., Wong, V. W., Yip, T. C., & Wu, C.-Y. (2026) · Liver International · doi:10.1111/liv.70534 · Cited by 2
N 6 ‐Methyladenosine (m 6 A) in Liver Disease: Pathogenic Mechanisms and Therapeutic Potential
Chen, Y., Ya, R., Zhang, Z., Dong, S., Park, S. H., Seo, W., & He, Y. (2026) · iNew Medicine · doi:10.1002/inm3.70036 · Cited by 2
Clusmann, J., Koop, P., Zhang, D. Y., van Haag, F., Nahhas, O. S. M. E., Seibel, T., Žigutytė, L., Kaewdech, A., Caldéraro, J., Tacke, F., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1323 · Cited by 6
Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment
Kozlitina, J., Romeo, S., & Hobbs, H. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001758 · Cited by 2
New understanding of the molecular pathogenesis and therapeutic progress of hepatocellular carcinoma
Wang, W.-J., Yuan, H.-X., Xu, J.-Z., Wang, X.-D., Na, G.-W., He, K.-J., Sun, W., Li, R., Che, J., & Cheng, Y.-S. (2026) · Oncology Reviews · doi:10.3389/or.2026.1763632 · Cited by 2
Shirono, T., Iwaki, M., Seko, Y., Jun, D. W., Shima, T., Takahashi, H., Kawanaka, M., Tanaka, S., Yamaguchi, K., Yoneda, M., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.04.026 · Cited by 2
Molecular mechanisms and pathogenesis of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10529-0 · Cited by 3
Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts
Kubota, N., Fujiwara, N., & Hoshida, Y. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.01.005 · Cited by 2
Jamialahmadi, O., Salehabadi, E., Hashemi‐Najafabadi, S., Motamedian, E., Bagheri, F., Mancina, R. M., & Romeo, S. (2022) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2022.0122 · Cited by 2
Risk of Liver Cancer in MASLD: Role of Genetic Risk Scores
Maccali, C., Pereira, I. V. A., Stefano, J. T., & de Oliveira, C. P. M. S. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00623-6 · Cited by 2
Yang, J., Tian, C., Liu, M., Guo, H., Lin, F., Ding, Y., Yao, W.-T., Zhang, J., Fan, J., Yu, C., et al. (2024) · Nutrients · doi:10.3390/nu16234212 · Cited by 2
Choi, J., & Kim, H.-S. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00684-9 · Cited by 2
Fujioka, K. (2022) · International Journal of Clinical Case Reports and Reviews · doi:10.31579/2690-4861/203 · Cited by 2
Chrysavgis, L., & Cholongitas, Ε. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21938-2.00020-5 · Cited by 3
Non-Alcoholic Fatty Liver Disease and Steatohepatitis
Govaere, O., & Anstee, Q. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00265-0 · Cited by 2
Díaz, L. A., Arrese, M. A., & Arab, J. P. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-386 · Cited by 2
Screening Potential Drugs for the Development of NAFLD Based on Drug Perturbation Gene Set
Gao, Z., Dai, L., & Zhang, H. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/7606716 · Cited by 1
The Genetics of Alcohol-Related Liver Disease
Innes, H. A., & Stickel, F. (2023) · Springer eBooks · doi:10.1007/978-3-031-32483-3_52 · Cited by 1
Genetic research on MASLD: New insights into cardiovascular disease and cancer risk
Yang, M., & Liu, J. (2024) · iLiver · doi:10.1016/j.iliver.2024.100108 · Cited by 1
Yin, Y., Du, Y., Xu, Y., Zhu, Z., Hu, Y., Xu, L., Yang, K., Chen, T., Shi, Y., Wang, C., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050338 · Cited by 1
Longo, M., Paolini, E., Meroni, M., Ripolone, M., Napoli, L., Gentile, F., Cespiati, A., Trombetta, E., Lombardi, R., Maggioni, M., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101539 · Cited by 1
Cumulative lipid exposure in young adulthood and risk of midlife MASLD
Chen, Y., Zheng, Y., Zhao, L., Gao, T., Qu, Y., Carr, J. J., Terry, J. G., Ning, H., Kim, K., Long, M. T., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101679 · Cited by 1
Zhao, L., Zhang, X., Zheng, J., Chen, Y., Haslam, D. E., Zeng, H., Hu, F. B., Hu, F. B., Tobias, D. K., McGlynn, K. A., et al. (2025) · Nature Food · doi:10.1038/s43016-025-01266-0 · Cited by 1
Metadata
- Authors
- Bianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., Borroni, V., D’Ambrosio, R., Spagnuolo, R., Alisi, A., Federico, A., Bugianesi, E., Petta, S., Miele, L., Vespasiani-Gentilucci, U., Anstee, Q. M., Stickel, F., Hampe, J., Fischer, J., Berg, T., Fracanzani, A. L., Soardo, G., Reeves, H., Prati, D., Romeo, S., & Valenti, L.
- Affiliations
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Sahlgrenska University Hospital (SE)
- University of Milan (IT)
- University of Udine (IT)
- Agostino Gemelli University Polyclinic (IT)
- Bambino Gesù Children's Hospital (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- University of Palermo (IT)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- University Hospital Zurich (CH)
- University Hospital Carl Gustav Carus (DE)
- University Hospital Leipzig (DE)
- Corresponding author
- Romeo, Stefano
- Valenti, Luca
- ORCID
- Bianco, Cristiana
- Jamialahmadi, Oveis
- Pelusi, Serena
- Baselli, Guido
- Dongiovanni, Paola
- Maier, Silvia
- Liguori, Antonio
- Meroni, Marica
- Borroni, Vittorio
- D’Ambrosio, Roberta
- Spagnuolo, Rocco
- Alisi, Anna
- Federico, Alessandro
- Bugianesi, Elisabetta
- Petta, Salvatore
- Miele, Luca
- Anstee, Quentin M.
- Stickel, Felix
- Hampe, Jochen
- Fischer, Janett
- Berg, Thomas
- Fracanzani, Anna Ludovica
- Soardo, Giorgio
- Reeves, Helen
- Prati, Daniele
- Romeo, Stefano
- Valenti, Luca
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 74
- Issue
- 4
- Pages
- 775-782
- ISSN
- 0168-8278 (ISSN-L)
- PMC
- PMC7987554
- OpenAlex
- W3106622583
- Cited by
- 385
- References
- 37
- Citations by year
- 2026: 60 · 2025: 60 · 2024: 68 · 2023: 80 · 2022: 64 · 2021: 52
- FWCI
- 35.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Hepatology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Institutional Research Information System (University of Udine) (submittedVersion, cc-by-nc-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_169196)
- Marianne and Marcus Wallenberg Foundation (KAW 2017.0203)
- Knut och Alice Wallenbergs Stiftelse
- Swiss Foundation for Alcohol Research
- AbbVie
- Akebia Therapeutics
- Amgen
- Novo Nordisk
- Novo Nordisk Fonden (DIA 2017-205, 9321-430)
- Hjärt-Lungfonden (20120533)
- European Research Council
- Seventh Framework Programme
- Diabetesförbundet
- Sanofi
- Pfizer
- Celgene
- Vetenskapsrådet (2016-01527)
- European Commission
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (RC100017A)
- Associazione Italiana per la Ricerca sul Cancro (16888)
- Ministero della Salute (RF-2016-02364358)
- Cancer Research UK (C18342/A23390, C9380/A18084, C9380/A26813)
- Gilead Sciences
- AstraZeneca
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- hepatocellular carcinoma, non-alcoholic fatty liver disease, polygenic risk score, HCC risk stratification, hepatic steatosis, liver fibrosis, PNPLA3, TM6SF2, GCKR, MBOAT7, HSD17B13, genetic susceptibility, liver cirrhosis, HCC detection, UK Biobank
- MeSH terms
- Mediation Analysis, Cross-Sectional Studies, Europe, Female, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Predictive Value of Tests, Prognosis, Risk Factors, Risk Assessment, Genetic Predisposition to Disease, Multifactorial Inheritance, Adiposity, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
